Takeda Launches Cinryze In India For Prophylaxis In Hereditary Angioedema Patients

Biopharmaceutical Major Takeda Biopharmaceuticals India Private Limited (Formerly Known As Baxalta Bioscience India Pvt. Ltd.) Has Launched Cinryze, An Innovative Injectable Prescription Medicine For The Treatment Of Hereditary Angioedema (Hae) Patients.With Eight Years Of Global Clinical Experience Proving Efficacy And Safety, Cinryze Has The Potential To Mark A Breakthrough In The Episodic Treatment, Short And Long-Term Prophylaxis For Hae.Moreover, Cinryze Is The Pioneer C1 Esterase Inhibitor (C1-I Nh) Approved By The Us Food And Drug Administration (Fda) And European Medicines Agency (Ema) For The Symptomatic Management Of Hae And For Preventing Future Angioedema Attacks.Cinryze Is Indicated In India For Routine Prevention (Prophylaxis) Of Angioedema Attacks In Adults, Adolescents And Children 6 Years Of Age And Above With Hae, Treatment Of Angioedema Attacks And Pre-Procedure Prevention Of Angioedema Attacks In Adults, Adolescents And Children 2 Years Of Age And Above With Hae.The Disease Is Usually Identified By Recurrent Episodes Of Fluid Accumulation Outside The Blood Vessels, Causing Rapid Swelling Of Body Tissues. The Symptoms Of Hae Could Be Like An Allergic Reaction; However, The Potential Outcome Could Be Life-Threatening In Case Of Hae. Due To The Lack Of Awareness Among Healthcare Professionals, Hae Is Highly Underdiagnosed In The Country.Speaking At The Launch, Serina Fischer, General Manager, Takeda Biopharmaceuticals India Private Limited Said,

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!